A 1970s patent that changed the course of commercial biotechnology

A 1970s patent for recombinant DNA technology is highlighted by Nature on June 23, 2026, as a pivotal moment in commercial biotechnology. This patent, filed by Stanley Cohen and Herbert Boyer, laid the groundwork for genetically engineered organisms and the subsequent creation of life-saving drugs. The technology allowed scientists to cut and paste DNA from different sources, a breakthrough that enabled the production of human insulin by bacteria in 1982, marking the first genetically engineered drug approved by the U.S. Food and Drug Administration. This innovation spurred the growth of the biotechnology industry, leading to the development of numerous therapeutic proteins, vaccines, and diagnostic tools. The article also touches upon early experiments with anaesthetics derived from puffball mushrooms, showcasing the diverse scientific inquiries of the era. The enduring impact of the recombinant DNA patent underscores its significance in transforming medicine and agriculture, paving the way for advancements such as gene therapy and genetically modified crops.